Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASG12D Inhibitor MRTX1133.

Journal of proteome research - 1 Dec 2023

Orsburn Benjamin C

Abstract excerpt

Mutations in KRAS are common drivers of human cancers and are often those with the poorest overall prognosis for patients. A recently developed compound, MRTX1133, has shown promise in inhibiting the activity of KRASG12D mutant proteins, which is one of the main drivers of pancreatic cancer. To better understand the mechanism of action of this compound, I performed both proteomics and metabolomics on four...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Proteomics Techniques and Applications
Share to Cell Image Analysis Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic and Hepatic Oncology Research

Share to Pancreatic Neoplasms

Share to Proteomics

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 37983312
DOI: 10.1021/acs.jproteome.3c00212
PMCID: PMC10696623

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Metabolomic, Proteomic, and Single-Cell Proteomic Analysis of Cancer Cells Treated with the KRASG12D Inhibitor MRTX1133.PMID 37983312Read ↗

Metabolomic, proteomic and single cell proteomic analysis of cancer cells treated with the KRAS <sup>G12D</sup> inhibitor MRTX1133Semantic proximity Read ↗

Screening Metabolic Biomarkers in KRAS Mutated Mouse Acinar and Human Pancreatic Cancer Cells via Single-Cell Mass Spectrometry.Semantic proximity Read ↗

Defining and targeting adaptations to oncogenic KRAS <sup>G12C</sup> inhibition using quantitative temporal proteomicsSemantic proximity Read ↗

Defining and Targeting Adaptations to Oncogenic KRASG12C Inhibition Using Quantitative Temporal Proteomics.Semantic proximity Read ↗

Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.Semantic proximity Read ↗

A Small Molecule with Big Impact: MRTX1133 Targets the KRASG12D Mutation in Pancreatic Cancer.Semantic proximity Read ↗

Large pan-cancer cell screen coupled to (phospho-)proteomics underscores high-dose vitamin C as a potent anti-cancer agentSemantic proximity Read ↗

TMOD3 accelerated resistance to immunotherapy in KRAS-mutated pancreatic cancer through promoting autophagy-dependent degradation of ASCL4.Semantic proximity Read ↗

A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.Semantic proximity Read ↗

A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies.Semantic proximity Read ↗

Single Cell Proteomics Using a Trapped Ion Mobility Time-of-Flight Mass Spectrometer Provides Insight into the Post-translational Modification Landscape of Individual Human CellsSemantic proximity Read ↗

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.